Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study

2020; Oxford University Press; Volume: 60; Issue: 7 Linguagem: Inglês

10.1093/rheumatology/keaa771

ISSN

1462-0332

Autores

Jennifer C. E. Lane, James Weaver, Kristin Kostka, Talita Duarte‐Salles, Maria Tereza Fernandes Abrahão, Heba Alghoul, Osaid Alser, Thamir M. Alshammari, Carlos Areia, Patricia Biedermann, Juan M. Banda, Edward Burn, Paula Casajust, Kristina Fišter, Jill Hardin, Laura Hester, George Hripcsak, Benjamin Skov Kaas‐Hansen, Sajan Khosla, Spyros Kolovos, Kristine E. Lynch, Rupa Makadia, Paras Mehta, Daniel R. Morales, Henry Morgan-Stewart, Mees Mosseveld, Danielle Newby, Fredrik Nyberg, Anna Ostropolets, Rae Woong Park, Albert Prats‐Uribe, Gowtham Rao, Christian Reich, Peter R. Rijnbeek, Anthony G. Sena, Azza Shoaibi, Henry M. Spotnitz, Vignesh Subbian, Marc A. Suchard, David Vizcaya, Haini Wen, Marcel de Wilde, Junqing Xie, Seng Chan You, Lin Zhang, Simon Lovestone, Patrick Ryan, Daniel Prieto‐Alhambra,

Tópico(s)

Drug-Induced Ocular Toxicity

Resumo

Concern has been raised in the rheumatology community regarding recent regulatory warnings that HCQ used in the coronavirus disease 2019 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident depression, suicidal ideation or psychosis associated with HCQ as used for RA.

Referência(s)